Business Insights, May 2011, Pages: 102
in biomarker development and validation are assessed and case studies given of regulatory approvals of drugs and companion tests. Strategies for drug-diagnostic co-development are evaluated.
Features
Jain PharmaBiotech, Feb 2012, Pages: 534
ligands
Simultaneous measurement of several biomarkers for AD
Plasma biomarkers of drug response in AD
A serum protein-based algorithm for the detection of AD
Concluding remarks about biomarkers for AD
Business Insights, June 2009, Pages: 114
combinations in pipeline
Changing dynamics of the IVD industry
Biomarker discovery for existing drugsNextgeneration tests
Conclusions
Appendix
Research methodology
Glossary
Index
List
TriMark Publications, July 2011, Pages: 214
Structures Limit the Use of Genetic Biomarkers in Drug Development and How Should R&D Organizations Address This Problem?
8.15 How to Maximize Business Development through Biomarker Strategies?
8.16 What
Takeda Pacific, July 2008, Pages: 175
Status' Segment Totals and Shares
Table 16. Current and NextGeneration MDx Technology Development
Table 17. Technologies Market Share: Current vs. Next-Gen. vs. Future by Product Pipelines
Table 18
Business Insights, Nov 2009, Pages: 165
antisense therapeutics
Stem cells & regenerative medicines
Conclusions
Chapter 2 Application in R&D &
technological advances
The application of epigenetics in drugR&D
DNA methylation biomarkers
TriMark Publications, May 2011, Pages: 1784
. Adoption of biomarker development in clinical research provides great opportunities to identify patient subpopulations with differential drug responses and to uncover the underlying mechanisms. These data
Axis Research Mind, Nov 2011, Pages: 615
in the near future and leads the world. Among the technologies used, biomarkers accounts for the largest share of nearly 40% and is fastest growing market. RFID & Tagging represents the second highest growing
Takeda Pacific, Aug 2009, Pages: 177
Status and Future Outlook by Segments
- Price Trends
- Sales and Distribution Roadmap
- Healthcare Issues
- NextGeneration Bioarray Technology Roadmap
- Genetic Bioarray Service Provider Roadmap
- Current
Axis Research Mind, Nov 2011, Pages: 730
SCIENTIFIC SIGNS AGREEMENT TO ACQUIRE B.R.A.H.M.S. AG
RESOURCEFUL DRUG EXPLORED WITH TECAN'S FREEDOM EVO® 75
ROBOTICS AND PROTEOMICS: A PROMISING PARTNERSHIP FOR BIOMARKER DISCOVERY
BIOCISION INITIATED
Business Insights, Feb 2007, Pages: 105
Chapter 5 New R&D strategies in cancer
Summary
Introduction
Background
Oncogenomics
Scientific approaches
Small interfering RNA
Biologicals
Gene expression and biomarkers
Arrays
Drug delivery
Axis Research Mind, Nov 2011, Pages: 629
in the near future and leads the world.
Among the technologies used, biomarkers accounts for the largest share of nearly 40% and is fastest growing market. RFID & Tagging represents the second highest growing
Axis Research Mind, Nov 2011, Pages: 730
in the near future and leads the world.
Among the technologies used, biomarkers accounts for the largest share of nearly 40% and is fastest growing market. RFID & Tagging represents the second highest growing
Bizacumen Inc., Nov 2009, Pages: 262
diagnosed categories. However, this unmet requirement offers substantial opportunities for nextgeneration therapies. Though there is no curative medicine available at present, medications that provide
Business Insights, Sep 2006, Pages: 126
among players in the industry .
- Genotyping of known biomarkers will reduce drug toxicity problems and contribute to better dosing regimens, offering the potential for fewer drug withdrawals resulting
Takeda Pacific, Aug 2010, Pages: 150
&D. The report discusses important technologies, equipment and consumables including microarray, next-generation sequencing, PCR and other platforms. Topics such as microRNA and human stem cells are lightly
Axis Research Mind, Nov 2011, Pages: 615
delivers a microscopic view of regional market values. The major end-user areas discussed in the report are:
BY END-USE MARKETS
Pharmaceuticals (Biomarkers, Drug Discovery, Therapeutics, Clinical Trials
Axis Research Mind, Nov 2011, Pages: 771
SCIENTIFIC SIGNS AGREEMENT TO ACQUIRE B.R.A.H.M.S. AG
RESOURCEFUL DRUG EXPLORED WITH TECAN'S FREEDOM EVO® 75
ROBOTICS AND PROTEOMICS: A PROMISING PARTNERSHIP FOR BIOMARKER DISCOVERY
BIOCISION INITIATED
Axis Research Mind, Nov 2011, Pages: 656
EXPANSION WHICH REPLACES NEED OF BLOOD PRODUCTS
CALIPER AND COVARIS COLLABORATED TO SIMPLIFY NEXTGENERATION SEQUENCING
GILEAD SCIENCES SIGNS AGREEMENT TO ACQUIRE CALISTOGA PHARMACEUTICALS
BIOKRYO GMBH
